Screening for Depression and Suicide Risk in Children and Adolescents: US Preventive Services Task Force Recommendation Statement
- PMID: 36219440
- DOI: 10.1001/jama.2022.16946
Screening for Depression and Suicide Risk in Children and Adolescents: US Preventive Services Task Force Recommendation Statement
Abstract
Importance: Depression is a leading cause of disability in the US. Children and adolescents with depression typically have functional impairments in their performance at school or work as well as in their interactions with their families and peers. Depression can also negatively affect the developmental trajectories of affected youth. Major depressive disorder (MDD) in children and adolescents is strongly associated with recurrent depression in adulthood; other mental disorders; and increased risk for suicidal ideation, suicide attempts, and suicide completion. Suicide is the second-leading cause of death among youth aged 10 to 19 years. Psychiatric disorders and previous suicide attempts increase suicide risk.
Objective: To update its 2014 and 2016 recommendations, the US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of screening, accuracy of screening, and benefits and harms of treatment of MDD and suicide risk in children and adolescents that would be applicable to primary care settings.
Population: Children and adolescents who do not have a diagnosed mental health condition or are not showing recognized signs or symptoms of depression or suicide risk.
Evidence assessment: The USPSTF concludes with moderate certainty that screening for MDD in adolescents aged 12 to 18 years has a moderate net benefit. The USPSTF concludes that the evidence is insufficient on screening for MDD in children 11 years or younger. The USPSTF concludes that the evidence is insufficient on the benefit and harms of screening for suicide risk in children and adolescents owing to a lack of evidence.
Recommendation: The USPSTF recommends screening for MDD in adolescents aged 12 to 18 years. (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for MDD in children 11 years or younger. (I statement) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for suicide risk in children and adolescents. (I statement).
Comment in
-
Screening for Adolescent Depression and Suicide Risk.JAMA. 2022 Oct 18;328(15):1504-1505. doi: 10.1001/jama.2022.15223. JAMA. 2022. PMID: 36219421 No abstract available.
-
Screening for depression and suicide risk in children and adolescents.J Pediatr. 2023 Oct;261:113320. doi: 10.1016/j.jpeds.2022.12.022. J Pediatr. 2023. PMID: 37741679 No abstract available.
Summary for patients in
-
Screening for Depression and Suicide Risk in Children and Adolescents.JAMA. 2022 Oct 18;328(15):1570. doi: 10.1001/jama.2022.18187. JAMA. 2022. PMID: 36219439
Similar articles
-
Screening for Depression and Suicide Risk in Adults: US Preventive Services Task Force Recommendation Statement.JAMA. 2023 Jun 20;329(23):2057-2067. doi: 10.1001/jama.2023.9297. JAMA. 2023. PMID: 37338872
-
Screening for Anxiety in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.JAMA. 2022 Oct 11;328(14):1438-1444. doi: 10.1001/jama.2022.16936. JAMA. 2022. PMID: 36219403
-
Screening for Depression in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.Pediatrics. 2016 Mar;137(3):e20154467. doi: 10.1542/peds.2015-4467. Epub 2016 Feb 8. Pediatrics. 2016. PMID: 26908686
-
Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer: US Preventive Services Task Force Recommendation Statement.JAMA. 2022 Jun 21;327(23):2326-2333. doi: 10.1001/jama.2022.8970. JAMA. 2022. PMID: 35727271 Review.
-
Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement.JAMA. 2022 Aug 23;328(8):746-753. doi: 10.1001/jama.2022.13044. JAMA. 2022. PMID: 35997723 Review.
Cited by
-
Country-specific psychopharmacological risk of reporting suicidality comparing 38 antidepressants and lithium from the FDA Adverse Event Reporting System, 2017-2023.Front Psychiatry. 2024 Nov 1;15:1442490. doi: 10.3389/fpsyt.2024.1442490. eCollection 2024. Front Psychiatry. 2024. PMID: 39575192 Free PMC article.
-
Cost-Effectiveness of Perinatal Depression Screening: A Scoping Review.Appl Health Econ Health Policy. 2024 Oct 26. doi: 10.1007/s40258-024-00922-z. Online ahead of print. Appl Health Econ Health Policy. 2024. PMID: 39460885 Review.
-
Evaluating mental health support by healthcare providers for patients with atopic dermatitis: A cross-sectional survey.Skin Health Dis. 2024 Jun 15;4(5):e408. doi: 10.1002/ski2.408. eCollection 2024 Oct. Skin Health Dis. 2024. PMID: 39355722 Free PMC article.
-
Scoping review on mental health standards for Black youth: identifying gaps and promoting equity in community, primary care, and educational settings.Child Adolesc Psychiatry Ment Health. 2024 Sep 9;18(1):113. doi: 10.1186/s13034-024-00800-5. Child Adolesc Psychiatry Ment Health. 2024. PMID: 39252127 Free PMC article. Review.
-
Suicide Risk Factors in High School Students.Int J Environ Res Public Health. 2024 Aug 12;21(8):1055. doi: 10.3390/ijerph21081055. Int J Environ Res Public Health. 2024. PMID: 39200665 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
